Recombinant Plasma Protein Patents: Who Leads, White Space 2026
- 70.0% of all 397 records sit with just five assignees — this field is concentrated at the top, not fragmented.
- A61K and C07K dominate at 71.0% and 58.7% of records respectively, showing formulation and protein-engineering claims crowd the same ground.
- Filing rose 10% from 2021 to 2024 (10 to 11 records) — modest but real growth once the reporting lag is accounted for.
Filing growth compares 2021 (10 records) with 2024 (11) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 397 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Recombinant alternatives to plasma proteins replace donor-derived coagulation factors and other plasma fractions with cell-line-manufactured equivalents. The patent activity in this dataset spans 397 records filed or published between 2015 and mid-2026, covering claims on cell line development, post-translational modification, half-life extension, manufacturing cost reduction, and strategies for displacing plasma-derived products in the market. The search string ties recombinant coagulation factor or plasma protein subject matter directly to these translational and commercial concerns, rather than to recombinant protein production generally.
The technology sits at the intersection of protein engineering and formulation science: most records carry claims in medicinal preparations (A61K) and peptide/protein chemistry (C07K), with a substantial minority reaching into microbial and genetic engineering (C12N) for the underlying cell line work. Filing offices skew toward the United States, Europe, and Australia, with WIPO PCT filings indicating that assignees actively pursue multi-jurisdiction protection for their lead candidates.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
The dataset tracks 397 published records from 2015 through the 2026 data cut-off, with concentration and technology-class data drawn directly from the underlying search results.
A slow build, then a plateau
Filings peaked in 2018 at 38 records, well ahead of the 2021 figure of 10. The 2021-to-2024 window shows a 10% rise, from 10 to 11 records — a real but modest recovery. Because publication lags filing by roughly 18 months, the years closest to the 2026 cut-off understate actual filing activity and should not be read as a decline.
Formulation and protein engineering lead
A61K (medicinal preparations) appears on 71.0% of records and C07K (peptides and proteins) on 58.7%, confirming that most claims target formulation and molecular design rather than pure manufacturing process. C12N (microorganisms and genetic engineering) reaches 30.2% of records, marking the cell-line-development slice of the field, while G01N (testing) and A61M (delivery devices) remain minority categories under 10%.
Shares are the percentage of the 397 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Recombinant Alternatives to Plasma Proteins with Eureka
This page is one run against one query. Ask Eureka your own question about recombinant alternatives to plasma proteins and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
A method for the preparation of recombinant human prothrombin and fibrinogen (WO2014115087A2)
The present invention relates to a method for the production of a human coagulation factor. Specifically, the coagulation factor is produced in a human host cell. The invention also relates to the use of the recombinant human coagulation factor in medicine.Filed by Cencor Biotech Ltd., this record anchors the human-host-cell production route for coagulation factors within the dataset.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2016166014A1 | Combination therapy with coagulation factors and multispecific antibodies | 61 |
| 2 | US20180333493A1 | High concentration protein formulations with reduced viscosity | 59 |
| 3 | WO2017075619A1 | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | 58 |
| 4 | WO2010056765A2 | Antidotes for factor XA inhibitors and methods of using the same in combination with blood coagulating agents | 55 |
| 5 | US20150071925A1 | Liquid protein formulations containing viscosity-lowering agents | 49 |
| 6 | US20100125052A1 | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | 40 |
| 7 | US20190133937A1 | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delive… | 39 |
| 8 | WO2015038818A2 | Liquid protein formulations containing viscosity-lowering agents | 37 |
| 9 | WO2006089613A1 | Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein exp… | 37 |
| 10 | US8455439B2 | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents | 34 |
Citation counts reflect influence within the searched corpus and favour older filings; treat them as a signal of prior-art density, not current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern signals
Three patterns stand out once the ranking, trend, and technology-class data are read together.
Five assignees hold most of the claim space
The top five assignees combined account for 70.0% of all 397 records in scope, and the top ten reach 97.0%. A field this concentrated leaves little room for a new entrant to file broad composition-of-matter claims on established coagulation factor variants without running into prior art from the leaders.
Formulation claims outnumber pure process claims
With A61K present on 71.0% of records and C12N — the genetic engineering and cell line class — on only 30.2%, filers are more often protecting how a recombinant protein is formulated and dosed than how the underlying cell line is built. That split suggests manufacturing-process claims are comparatively less crowded than formulation claims.
Growth is real but slow
Filing volume rose from 10 records in 2021 to 11 in 2024, a 10% increase over three years, well below the 2018 peak of 38. Recent-year momentum data shows several of the largest historical filers recording zero filings in the latest tracked year, consistent with a field where the leaders have already staked their core claims.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to recombinant alternatives to plasma proteins, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Baxter International Inc. | Baxter Healthcare SA | 37 |
| Baxalta Inc. | Baxalta GmbH | 24 |
| The Children's Hospital of Philadelphia | SABATINO DENISE | 17 |
| The Children's Hospital of Philadelphia | HIGH KATHERINE A | 14 |
| The Children's Hospital of Philadelphia | ELKOUBY LIRON | 14 |
| Eagle Biologics, Inc. | Rani Therapeutics, LLC | 9 |
| Baxalta Inc. | Takeda Pharmaceutical Company Limited | 4 |
| Baxalta GmbH | Takeda Pharmaceutical Company Limited | 4 |
Only 10 co-assignee pairs appear in the dataset, and the strongest pair co-files at a level far above the others — a sign that cross-entity collaboration in this field runs through a small number of long-standing corporate relationships rather than broad industry partnering.
Who is filing, and where the claim space is still open
The ranked list covers 48 companies; a small number account for nearly all of the activity, while a long tail files once or twice.
One assignee dominates the ranking
The leading assignee holds 124 records, more than four times the fifth-place total of 30. This gap indicates a single filer built a defensive portfolio early and has continued to add to it across formulation, dosing, and manufacturing claims.
A steep drop after the leaders
Fifth place sits at 30 records and tenth place at 15 — roughly half — showing the mid-tier is still meaningfully active but filing at a fraction of the leader's rate. Co-assignee data shows several of these mid-tier filers are related corporate entities rather than independent competitors.
A long tail of single- and few-filing entrants
Beyond the top ten, which already account for 97.0% of all 397 records, the remaining companies in the 48-company ranking file in small numbers. This is where new entrants with narrow, well-drafted claims are most likely to find open ground rather than in the crowded top tier.
| Assignee | Recent year | YoY |
|---|---|---|
| Eagle Biologics, Inc. | 0 | — |
| Spark Therapeutics, Inc. | 0 | — |
| Rani Therapeutics, LLC | 0 | — |
| Baxter International Inc. | 0 | — |
| Baxter Healthcare SA | 0 | — |
| Rani Therapeutics, LLC | 0 | — |
| Baxalta Inc. | 0 | — |
| Baxalta GmbH | 0 | — |
Where to take this analysis
The dataset points to specific follow-up work depending on whether the goal is freedom-to-operate, licensing, or new filing strategy.
Map claims against the top five assignees
With 70.0% of records held by five companies, a freedom-to-operate review should start by pulling their full claim sets in A61K and C07K before drafting new composition or formulation claims.
Explore assignee claims in EurekaTest white-space branches for prior art density
Sub-areas like non-Fc half-life extension and immunogenicity testing methods show lighter representation in this dataset; a targeted prior-art search can confirm whether that gap is real or an artifact of the search string.
Run a white-space search in EurekaTrack post-2024 filings as they publish
Because publication lags filing by roughly 18 months, the 2025–2026 figures in this dataset will keep rising. Revisiting the trend in six to twelve months will clarify whether the 2021–2024 growth continues.
Set up a monitoring alert in EurekaCommon questions on recombinant plasma protein patents
The dataset behind this landscape ranks 48 companies, with the leading assignee holding 124 of the 397 records in scope — more than four times the fifth-place total of 30. The top five assignees combined account for 70.0% of all records, meaning most of the claim space is controlled by a small group rather than spread evenly. Anyone doing freedom-to-operate work in this field should start with that top tier before looking at the long tail of smaller filers.
Filing peaked in 2018 at 38 records and has not returned to that level; the most recent complete comparison shows a rise from 10 records in 2021 to 11 in 2024, a 10% increase. That is modest growth rather than a boom. Because patent publication typically lags filing by about 18 months, the 2025 and 2026 figures in any dataset covering this period will look artificially low and should not be read as a slowdown.
A61K (medicinal preparations) appears on 71.0% of the 397 records in this landscape and C07K (peptides and proteins) on 58.7%, making these the two dominant classes. C12N (microorganisms and genetic engineering), which covers the underlying cell line work, appears on 30.2% of records. Because a single patent can carry several IPC classes, these percentages add up to more than 100% and should not be summed or treated as mutually exclusive categories.
WO2014115087A2, filed by Cencor Biotech Ltd., covers a method for producing recombinant human prothrombin and fibrinogen in a human host cell, along with the use of the resulting recombinant coagulation factor in medicine. The claim scope centres on the human-host-cell production route specifically, rather than recombinant coagulation factor production in general. Anyone working on a competing cell-line-based production method for these two proteins should review this filing's claim boundaries directly rather than relying on the abstract alone.
The technology composition data shows lighter claim density outside the core A61K/C07K formulation space — specifically in delivery-device integration (A61M, 4.5% of records), analytical and testing methods (G01N, 7.6%), and fermentation/enzymatic synthesis process claims (C12P, 8.8%). These lower-density classes are candidates for new filing strategies, though a targeted prior-art search is needed to confirm the gap holds once narrower search terms are applied. The concentrated top tier of assignees makes these adjacent branches a more realistic entry point than the crowded coagulation-factor core.
Research Recombinant Alternatives to Plasma Proteins in depth with Eureka
Go past this page: query the whole recombinant alternatives to plasma proteins corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.